Article Figures & Data
Figures
- Figure 1.
Determination of the half-maximum inhibitory concentration (IC50) of eribulin in 12 triple-negative breast cancer (TNBC) and five non-TNBC cell lines. a: Boxplot of the log IC50 concentration of eribulin for each cell line, with 95% confidence interval (CI). b: Comparison of the IC50 of TNBC vs. non-TNBC. c: Comparison of the IC50 among each subtype of TNBC. BL1: basal-like 1, BL2: basal-like 2, IM: immunomodulatory, M: mesenchymal, MSL: mesenchymal stem-like, LAR: luminal androgen receptor, U: unclassified.
- Figure 2.
Induction of apoptosis by eribulin treatment. a: Fluorescence-activated cell sorting (FACS) analysis in MDA-MB-468 triple-negative breast cancer (TNBC) and MCF-7 (non-TNBC) indicated increased apoptosis [early (Q2) and late (Q3)] after treatment with 10× the half-maximum inhibitory concentration (IC50) of eribulin for 24 h. b: Poly (ADP-ribose) polymerase (PARP) cleavage in western blot analyses in TNBC cell lines validated apoptosis induction by eribulin (Eri) (IC50 for 24 h), Con: Untreated, CAM: camptothecin treated (positive control).
- Figure 3.
Decrease of migration and invasion after eribulin treatment. a: A vertical scratch crossing the green line indicates the cell-free area. Cells migrating into the area were observed after 24 h. b: Invasion assays were performed with MDA-MB-231 cells seeded on Matrigel-coated Transwells in 24 well plates. After 24 h incubation, untreated cells and cells treated with the half-maximum inhibitory concentration (IC50) of eribulin that had migrated to bottom surfaces of the membranes were visualized by staining with Giemsa solution.
- Figure 4.
Gene expression changes after treatment with eribulin. The expression of gamma-aminobutyric acid type A receptor pi subunit (GABRP) (a) and (E74-like ETS transcription factor 5) ELF5 (b) after treatment with eribulin at the half-maximum inhibitory concentration (IC50) for 24 h compared to untreated controls in cell lines representing all triple-negative breast cancer (TNBC) subtypes and non-TNBC. c: The expression of tumor-related genes after eribulin treatment in four cell lines representing the TNBC subtypes basal-like 1 (BL1) (MDA-MB-468), BL2 (HDQ-P1), immunomodulatory (IM) (DU-4475) and mesenchymal stem-like (MSL) (MDA-MB-231). Expression ratios are shown as 2-log scale values. LAR: Luminal androgen receptor, U: unclassified. *Significantly different from the control at p<0.05.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Integrating Mathematical Modeling with High-Throughput Imaging Explains How Polyploid Populations Behave in Nutrient-Sparse Environments
- Invasion of homogeneous and polyploid populations in nutrient-limiting environments
- Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines